NASDAQ · ENGNW
Healthcare · Biotechnology
$0.17
Down-$0.03 (-14.88%)
Updated Oct 9, 2026, 4:03 AM
SID Score
2.8/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · ENGNW
1M range · 9 trading sessions · Daily adjusted prices
Prices through Oct 5, 2026
ENGNW closed at $0.17 after 9 trading sessions, down 26.09% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 5, 2026 | $0.25 | $0.25 | $0.1416 | $0.17 | 63.67K |
| Sep 30, 2026 | $0.2001 | $0.2001 | $0.2001 | $0.2001 | 3.46K |
| Sep 29, 2026 | $0.20 | $0.2126 | $0.20 | $0.2009 | 13K |
| Sep 25, 2026 | $0.259 | $0.259 | $0.2201 | $0.2201 | 9.72K |
| Sep 23, 2026 | $0.34 | $0.34 | $0.34 | $0.34 | 100 |
| Sep 22, 2026 | $0.27 | $0.27 | $0.2499 | $0.2499 | 1.2K |
| Sep 21, 2026 | $0.25 | $0.25 | $0.25 | $0.25 | 7.4K |
| Sep 14, 2026 | $0.1802 | $0.27 | $0.1802 | $0.20 | 16.5K |
| Sep 11, 2026 | $0.23 | $0.23 | $0.23 | $0.23 | 1.81K |
The latest Smart Investors Daily articles mentioning ENGNW.
Company
Market Activity
Research & News
ENGNW research
Company profile and research snapshot.
enGene Holdings Inc is a clinical-stage biotechnology company focused on developing gene therapies to improve the lives of patients. The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.
Visit company websiteConsensus and target data currently published for this company.
No generated briefing is available yet.
SeekingAlpha · Sep 14, 2026
enGene Therapeutics Inc. (ENGN) Morgan Stanley 24th Annual Global Healthcare Conference September 14, 2026 7:00 AM EDTCompany ParticipantsRonald H.
Yahoo · Sep 8, 2026
BOSTON & MONTREAL, September 08, 2026--enGene Therapeutics Inc. (Nasdaq: ENGN, "enGene" or the "Company"), a clinical-stage, non-viral genetic medicines company, today announced its financial results for the third quarter ended July 31, 2026, and provided clinical and corporate updates.
Yahoo · Sep 1, 2026
BOSTON & MONTREAL, September 01, 2026--enGene Therapeutics Inc. (Nasdaq: ENGN, "enGene" or the "Company"), a clinical-stage, non-viral genetic medicines company today announced that management will participate in the following investor conferences:
Yahoo · Aug 13, 2026
enGene (NASDAQ:ENGN) outlined its view of the high-risk Bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer, or NMIBC, market, citing market research that it believes supports a larger addressable patient population and greater use of treatment sequencing before radical cystecto
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning ENGNW.
